Navigation Links
Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
Date:8/20/2007

... with Sales Team Forming and Increased Space, Poised for Market Launch

KIRKLAND, Wash., Aug. 20 /PRNewswire/ -- Pathway Medical Technologies, Inc., which is developing innovative devices for the treatment of arterial disease, today announced that it has hired a VP of Sales, Joseph W. Rafferty, and has started building its sales team in preparation for the introduction of its first product, Pathway PV(TM) Atherectomy System.

Recently Pathway moved from its old 10,000-square-foot facility to a new state-of-the art 51,000-square-foot, cGMP (Good Manufacturing Practices) - compliant manufacturing facility at 10801 120th Ave NE in Kirkland. The new facility boasts a 6,500-square-foot clean room to meet anticipated market demand. Additional 3000-square-feet are available for future expansion purposes. In the last six months the company's staff has grown from 53 to 91, almost doubling the size of the company, and Pathway continues to add employees to prepare for its first product introduction.

Mr. Rafferty, who will be working out of the company's new headquarters, joins the Pathway executive team with more than 25 years of experience in the medical-device industry. He has held senior sales and marketing management positions at companies like ACS/Guidant, where his contributions led to its leadership position in interventional cardiology. In his role as the Midwest Region Sales Manager, he pioneered Guidant's highly successful P3 (price-per- procedure) program, which ultimately redefined the reimbursement model for interventional cardiology.

"Joe brings extensive field sales, sales management and operational management experience to our team. He will be a significant contributor to the success of Pathway's premier new product. He knows how to build a leading sales organization for a category leader," said Pathway CEO and President Tom Clement.

"When you have a product about to launch with all the hallmarks of a category leader, it's exhilarating!" commented Mr. Rafferty. "My first task is to build a formidable and experienced sales team as quickly as possible."

"I am delighted to be joining the Pathway Medical team at such an exciting time. We are well-positioned for terrific growth as we commercialize the Pathway PV Atherectomy System," he said.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to develop, manufacture and market medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. An estimated 14 million people are afflicted by PAD in the United States, and that number is projected to grow to over 20 million during the next 10 years. The company's Pathway PV System allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue.

Nine months ago, the company passed a major milestone when it received a $25 million Series B round of financing from five venture capital investors.

Company Contact:

Thomas J. Clement

CEO/President

(425)636-4122

clementt@pathwaymedical.com


'/>"/>
SOURCE Pathway Medical Technologies, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. In Vivo Signal Transduction Pathway Reporting Systems
4. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
5. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
6. Medical College receives $377K to study brain disease
7. Barriers will not stop convergence of medical technologies
8. Medical College team creates website for tracking flu
9. Biomedical engineering conference invites manufacturers
10. Visions: Wade offers straight talk on e-medical records
11. Merge unveils updated medical imaging software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):